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The small protein AcrZ in Escherichia coli interacts with the transmembrane 
portion of the multidrug efflux pump AcrB and increases resistance of the 
bacterium to a subset of the antibiotic substrates of that transporter. It is not clear 
how the physical association of the two proteins selectively changes activity of the 
pump for defined substrates. Here, we report cryo-EM structures of AcrB and the 
AcrBZ complex in lipid environments, and comparisons suggest that 
conformational changes occur in the drug binding pocket as a result of AcrZ 
binding. Simulations indicate that cardiolipin preferentially interacts with the 
AcrBZ complex, due to increased contact surface, and we observe that 
chloramphenicol sensitivity of bacteria lacking AcrZ is exacerbated when 
combined with cardiolipin deficiency. Taken together, the data suggest that AcrZ 
and lipid cooperate to allosterically modulate AcrB activity. This mode of regulation 
by a small protein and lipid may occur for other membrane proteins.   
 









Numerous small proteins, corresponding to 100 or fewer codons, are encoded by 
phylogenetically diverse organisms and are likely to play key roles in many fundamental 
biological processes (Storz et al., 2014). Some small proteins have been discovered to 
regulate activity of large transport proteins, and in Escherichia coli, the 49 amino acid 
AcrZ modulates the action of AcrB, a homotrimeric secondary-active transporter that 
belongs to the resistance-nodulation-cell division (RND) superfamily (Hobbs et al., 2012). 
Deletion of the acrZ gene renders E. coli cells more sensitive to a subset of the antibiotics 
for which AcrB provides resistance (Hobbs et al., 2012). Transcription of acrZ is co-
regulated with the acrAB operon, which also implicates the functional importance of the 
small protein for efflux activity (Hobbs et al., 2012).   
 AcrB is the energy-transducing component of a tripartite multi-drug efflux 
machinery that includes the outer membrane protein TolC and the periplasmic bridging 
partner AcrA. Structures of the fully assembled tripartite complex together with AcrZ have 
been elucidated using cryo-electron microscopy (Du et al., 2014; Jeong et al., 2016; 
Wang et al., 2017b), revealing that the small protein forms a transmembrane helix which 
interacts extensively with the concave surface of AcrB in the transmembrane region. The 
interaction of AcrZ and AcrB in situ has been corroborated by mass spectrometry of the 
intact complex ejected directly from native membranes of E. coli cells (Chorev et al., 
2018). 
 While its influence over AcrB remains unclear from the available data, AcrZ was 
hypothesized to alter the conformation of the drug binding pockets during the transport 
cycle and so change drug specificity. In this model, AcrZ could exert an influence on AcrB 
by changing the shape of the surface that is exposed to the lipid from a concave to a 
convex curvature, thus potentially affecting the interactions with lipids and distribution of 
lateral forces of the bilayer that can be communicated into the core of the transporter. In 
support for this proposal, experimental findings in other systems indicate that lipids and 
the membrane composition can have profound effects on structure, oligomerization and 
activity of membrane proteins (Bechara et al., 2015; Gupta et al., 2017; Laganowsky et 
al., 2014). Moreover, a recent cryo-EM study of AcrB extracted directly from membranes 
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reveals a semi-crystalline lipid organization within the central region of the 
transmembrane domains of the AcrB trimer that may support quaternary state transitions 
required for the transport mechanism (Qiu et al., 2018). 
 To investigate how AcrZ impacts AcrB, we determined cryo-EM structures of AcrB 
and the AcrBZ complex reconstituted in a disc in which a bilayer of E. coli lipids is 
encircled by the membrane scaffold protein saposin A (Frauenfeld et al, 2016). To 
facilitate particle alignments for 3D reconstructions, the complexes included an 
engineered DARPin protein that binds the periplasmic domain of AcrB (Eicher et al., 2012; 
Sennhauser et al., 2006). Trimeric AcrB cycles through three states in the transport 
process, and DARPin associates with the subunits in the loose (L) and tight (T) states, 
but not with the periplasmic region of the open state (O). These three states can be 
observed in the cryo-EM reconstructions, enabling analysis of the AcrZ interactions with 
each state. We conclude that the combination of AcrZ and lipid environment work 
synergistically to provide an allosteric effect on the conformation of AcrB, with functional 






Cryo-electron microscopy of DARPin-bound AcrB and AcrBZ reconstituted into 
saposin A discs  
We developed a procedure to reconstitute purified E. coli AcrB and the AcrBZ complex 
into discs using E. coli lipids and saposin A as scaffolding protein (details in Materials and 
Methods). The reconstituted specimens behaved well on size exclusion chromatography 
and eluted with a gaussian shaped profile in buffer without detergent that is otherwise 
required to keep the membrane proteins soluble. To facilitate particle alignment from cryo-
EM images of these specimens, we included an engineered DARPin that binds the 
periplasmic domain of AcrB (Eicher et al., 2012; Sennhauser et al., 2006). The disc-
reconstituted, DARPin-bound AcrB and AcrBZ samples yielded excellent quality particles 
on cryo-EM grids (Appendix Fig S1A and S1B). Analysis of the particles provided 
interpretable maps with resolutions near 3.2 Å based on Fourier shell correlations. Models 
could be built into the density and refined with good stereochemistry (Appendix Table 
S1). Top, bottom and side views of AcrB and AcrBZ are shown in Fig 1. 
Saposin A monomers, which form a ring around the transmembrane domain of 
AcrB and the AcrBZ complex, were also resolved at a lower density, indicating that the 
ring is associated flexibly with the transporter. The features of the saposin A become 
more diffuse as refinement progressed, while the features of the AcrB and AcrBZ become 
sharper. A lipid layer could be visualized in the maps, and acyl chains or lipid head groups 
were included in the refined models.  
 A well-organised lipid bilayer within the central region of the transmembrane 
domains of the AcrB trimer was noted in earlier studies of specimens solubilised with 
styrene-maleic acid co-polymers (Qiu et al., 2018). We also observe a lipid layer in our 
maps in the corresponding region (Fig 2A). Our best model for the AcrBZ complex in 
saposin A discs is consistent with acyl chain packing observed in the structure of AcrB in 
co-polymers (Fig 2A).  Simulations show that the acyl chains on the inner leaflet pack in 
a stable lattice with approximate hexagonal geometry (Fig 2B), visible also in our cryo-
EM maps, while they form a less regular pattern in the outer leaflet. The calculations 
 6 
indicate that acyl chains are more mobile in the outer layer compared to the inner layer 
(Fig 2C). Hydrophobic side chains of AcrB are predicted to interact with the acyl groups 
of these lipids in different ways for the three protomers (Fig 2D); such differences could 
help to communicate conformational signals between the subunits associated with 
transitions between the L, T, and O states, as proposed earlier (Qiu et al., 2018).  Density 
is also present for lipids on the outer surface where AcrZ interacts, but the lipids here are 
not extensively ordered. 
 
The lipid environment affects the orientation of AcrZ on AcrB  
The models of AcrB and AcrBZ in the saposin discs were compared against previously 
described crystal structures of detergent-solubilised AcrB and AcrBZ, respectively (Fig 3). 
As a reference frame for the comparison, we used transmembrane helices (TMH) 4-6, 
which had previously been demonstrated to be a suitable group for overlays due to its 
conformationally invariance in the L, T and O states (Murakami et al., 2006; Seeger et al., 
2006).  Small conformational shifts were detected between the detergent-based crystal 
structure and the saposin disc-reconstituted cryo-EM structure for both AcrB and AcrBZ, 
including a rotation of the periplasmic domain (foremost in PC2, PN2 and PC1 sub-
domains) in all three states (L, T and O). These differences in the periplasmic domain 
could reflect the response of the protein to constraints imposed or enforced by the crystal 
lattice. A structural comparison of AcrB and AcrBZ when both are in saposin A discs 
indicates small changes in all three AcrB protomers in PC1/2 and PN2 and TMH2 and 8 
(Appendix Fig S2).  These changes may be a consequence of the presence of AcrZ. 
In the AcrBZ structure in saposin A discs, we noted a previously unseen, significant 
bending of AcrZ towards the binding groove in AcrB, which was most pronounced in L 
and O states. Each of the three AcrZs in the saposin disc bends towards AcrB between 
residues 10 and 15 (F10, A11, V12, I13, M14, V15) (Fig 4A and 4B). The bending mode 
is also predicted by molecular dynamics simulations of the AcrBZ complex in a lipid bilayer 
(Fig 4C). The bend could be caused by the presence of lipids in the saposin disc 
mediating new contacts with AcrB or otherwise exerting a force on AcrZ.  
 
Defined bend in AcrZ important for interaction with AcrB and effect on efflux  
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A proline at position 16 is expected to be a helix-breaker (Fig 4D), conferring a kink to the 
AcrZ protein due to the R-group ring. Given the significant bending seen in this region in 
the structural analysis, we asked whether the proline residue is important for the AcrZ 
interaction with AcrB. Using a two-hybrid approach with AcrB and AcrZ fused to the T25 
and T18 fragments of Bordetella pertussis adenylate cyclase, respectively, we assayed 
for interactions that restore adenylate cyclase function, and consequently induce β-
galactosidase activity (Hobbs et al., 2012). We first substituted an alanine for the proline 
residue (P16A) and observed that for this mutant the β-galactosidase activity was 
equivalent to empty vector levels, indicating the P16A variant could not interact with AcrB 
(Fig 4E). We then shifted the location of the proline from position 16 to positions 17, 18, 
19 and 20 (P16A V17P, P16A V18P, P16A M19P, P16A A20P). With the exception of 
P16A V18P, all mutations restored β-galactosidase activity to wild type levels (Fig 4E). 
We next examined the consequences of introducing a second proline at positions 19 and 
20 (M19P, A20P). The M19P and A20P variants had reduced β-galactosidase compared 
to wild type. Finally, we investigated the effect of changing flexibility in this region by 
introducing single and double glycine substitutions (P16G, V15G P16G, P16G V17G). In 
principle, glycine could permit the AcrZ to bend in the same conformation favoured by 
proline, and indeed all glycine substitution AcrZ variants were able to interact with AcrB 
at wild type levels (Fig 4E). Together, these results indicate that a bend in AcrZ around 
position 16 is important for the AcrZ-AcrB interaction. 
To investigate the effects of AcrZ mutations on drug efflux, untagged derivatives 
were expressed from a plasmid in a ∆acrZ strain background and assayed for resistance 
to chloramphenicol. Compared to the vector control, wild type acrZ provided increased 
resistance to chloramphenicol on gradient plates (Fig 4F). As expected, mutant AcrZ 
variants unable to interact with AcrB were unable to rescue chloramphenicol resistance. 
However, several AcrZ mutants capable of interacting with AcrB were nonetheless unable 
to restore growth to wild type levels (V15G P16G; P16G V17G). Interestingly two mutants 
that had a wild type or intermediate phenotype for AcrB interaction (P16A M19P; M19P) 
showed reduced chloramphenicol resistance to below that of the empty vector, while two 
other mutants with a wild type AcrB interaction (P16A A20P; A20P) were more resistant 
than the wild type AcrZ strain.  
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Interestingly, mutations of individual interfacial residues to alanine did not have a 
strong effect on either the AcrZ interaction with AcrB or chloramphenicol resistance 
(Appendix Fig S3). Together, these results indicate that the overall hydrophobic character 
and bent shape of AcrZ, rather than specific AcrB-AcrZ contacts, are important for 
physical interactions. Moreover, the mutations also indicate that direct interactions of 
AcrB-AcrZ are necessary but not sufficient for efflux function, and that the interactions 
can either suppress or support pump activity depending on context. These features are a 
hallmark of an allosteric system. 
 
Lipid interactions with AcrB and AcrBZ 
It had previously been suggested that lipids can modulate the structure and function of 
specific membrane proteins, and cardiolipin has been identified as such a modulator 
(Bechara et al., 2015; Gupta et al., 2017; Laganowsky et al., 2014). We carried out 
coarse-grained molecular dynamics simulations of AcrB and AcrBZ with E. coli 
cytoplasmic membrane model composed of mostly palmityloleoyl 
phosphatidylethanolamine (POPE), but also including cardiolipin and palmityloleoyl 
phosphatidylglycerol (POPG), which are the least abundant lipids in the natural 
cytoplasmic membrane. Our simulations started with no cardiolipin and POPG molecules 
within 30 Å of the protein, but after 5 µs as many as 15 cardiolipin and 50 POPG 
molecules were found within 6 Å of the protein (Appendix Fig S4). The cardiolipin and 
POPG enriched around both proteins despite the membrane containing a smaller number 
of these lipid types compared to palmityloleoyl phosphatidylethanolamine (POPE). A 
slightly higher degree of enrichment was observed around AcrBZ compared to AcrB, 
especially in the case of POPG. Analysis of density plots suggest that the interaction 
between these lipids with AcrB or AcrBZ may be non-specific, as high-density regions 
were found around all parts of the transmembrane portion of the proteins (Appendix Fig 
S4). The higher number of cardiolipin and POPG for AcrBZ is likely to result from the 
increase protein surface area (Appendix Fig S4D). Given that it is easier to genetically 
manipulate the cardiolipin composition of the E. coli inner membrane, we focussed our 
functional and structural studies on this special lipid. 
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The E. coli inner membrane has been reported to contain around 5% cardiolipin 
(Dowhan, 1997), with some localized enrichment in negatively curved regions of the 
membrane such as the cell poles (Renner and Weibel, 2011).  To test the effects of 
cardiolipin on the conformation of AcrB and AcrBZ, we reconstituted the proteins into 
saposin discs in which the E. coli lipids were supplemented with an additional 5% 
cardiolipin (i.e., to ~10% total abundance). The increase in the cardiolipin content is 
associated with small changes in PC1/2 and PN2 for AcrB (Appendix Fig S2). Minor 
changes were seen when comparing the AcrBZ complexes in the presence and absence 
of excess cardiolipin. The greatest changes were seen in comparing AcrB with natural 
lipids with AcrBZ in the lipid environment with added cardiolipin (Appendix Fig. S2). 
 
Additive effects of AcrZ and cardiolipin for growth viability and drug binding 
E. coli lacking AcrZ was previously shown to be less resistant to chloramphenicol 
compared to the wild type parental strain (Hobbs et al., 2012). Due to the conformational 
changes in AcrB observed in the presence of AcrZ and additional cardiolipin, we asked 
whether cardiolipin could affect chloramphenicol resistance. Thus the wild type strain (E. 
coli MG1655) and strains lacking AcrZ (MG1655 ∆acrZ), cardiolipin (MG1655 
∆clsABC::FRT-kan-FRT) or both (MG1655 ∆clsABC::FRT-kan-FRT ∆acrZ) were assayed 
for chloramphenicol resistance. As reported previously, the acrZ deletion strain showed 
increased sensitivity to chloramphenicol but not erythromycin (Hobbs et al., 2012) (Fig 5). 
Strains deficient for cardiolipin also were more sensitive to chloramphenicol. Strikingly, 
the double mutant strain was most sensitive to chloramphenicol, consistent with the 
largest structural changes being seen in the presence of both AcrZ and cardiolipin. These 
results indicate AcrZ and cardiolipin have additive effects on AcrB ability to export 
chloramphenicol (Fig 5).  
 
Combination of AcrZ and cardiolipin is associated with changes in the AcrB entry 
channels, gating loop and binding pocket 
Efflux of substrates through AcrB is complex process given that AcrB has multiple entry 
channels and multiple binding sites that are used by different types of drugs (reviewed 
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in (Zwama and Yamaguchi, 2018)). Deletion of acrZ affects only a subset of the 
antibiotics effluxed by AcrB. The mechanism behind this specificity is unknown, but it is 
possible that AcrZ is selectively affects certain entry channels or binding locations. 
Thus, we examined structural differences in AcrB regions involved in drug transport in 
the presence and absence of AcrZ and cardiolipin. For the AcrB set, we used 
minocycline as ligand, and for AcrBZ, we used chloramphenicol. We found AcrZ and 
cardiolipin affect both of the substrate entry channels (Fig 6A and Appendix Fig S5). 
Channel 1, for entry from the periplasm, has an altered entry shape with closer access 
from above the membrane surface in AcrBZ compared to AcrB. Channel 2, which 
protrudes sideward from above the outer leaflet of the membrane into the protomer in 
the L state, is more restricted by a loop region part of PC1/2 of the AcrB structure in a 
saposin disc without cardiolipin enrichment when compared to AcrBZ structure in the 
saposin disc with ~10% cardiolipin.  
There are also changes in the switch loop that could influence the passage of the 
drug from the L to the T states (Fig 6B).  To explore the process of substrate movement 
through the pocket, molecular dynamics simulations were conducted in which a 
chloramphenicol molecule was pulled from the periplasmic space into the deep binding 
pocket of the L protomer of AcrB and AcrBZ with 10% cardiolipin. The results of these 
simulations suggest that the movement of the antibiotic is unaffected by the switch loop 
at the entry gate of the ligand from the L to the T state due to its inherent flexibility 
(Appendix Fig S6). 
The observed changes in PC1/2 and PN2 of AcrB are likely to affect drug-binding 
pocket properties in the T protomer given the orientation of key residues for substrate 
binding (Fig 6C). When AcrBZ saposin discs with supplementary cardiolipin were 
prepared with the addition of chloramphenicol, additional density was found in the cryo-
EM map in the distal pocket of the AcrB protomer in the T state, which could be easily 
fitted with a molecule of the antibiotic (Fig 6D). The structural changes we observe are 
unlikely due to incubation with different substrates (minocycline versus chloramphenicol), 
because we do not observe density in the T or L pockets for either minocycline (in AcrB 
+/- cardiolipin with saposin A) or chloramphenicol (in the AcrBZ complex without 
additional cardiolipin with saposin A). We also tested chloramphenicol with one of the 
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preparations of AcrB in saposin A disks but did not see the ligand (results not shown). 
The chloramphenicol only becomes visible in the T state pocket in the case of AcrBZ with 
additional cardiolipin. These data suggest that the presence of AcrZ and cardiolipin can 
influence the occupancy of the substrate in the binding pocket. 
Molecular dynamics simulations also indicate that chloramphenicol is bound more 
stably to the binding site of the T protomer of the AcrBZ + 10% cardiolipin structure 
compared to the AcrB structure (Appendix Fig S7). Chloramphenicol significantly and 
frequently changed its orientation and failed to reach a stable conformation in the 
simulations of AcrB. Together the structures and simulations show that, although the 
effects of AcrZ and cardiolipin on the transport activity of AcrB might not occur at the 







The development of a procedure for efficient reconstitution of AcrBZ into saposin A-
scaffold based discs with a native lipid environment, suitable for cryo-EM analysis and 
with an option to alter the lipid content, revealed previously undescribed structural 
differences in the conformation of AcrZ. The structure, together with mutagenesis data, 
revealed that the overall bent shape of AcrZ is being recognized rather than specific 
interacting residues, which also may be the case for the transmembrane interactions of 
other small proteins with their cognate partners (Hobson et al., 2018). The elucidation of 
a more native conformation of both AcrB and the AcrBZ complex helps to explain the 
mechanism behind the resistance-modulating effect of AcrZ binding to AcrB for a subset 
of its substrates.  
In light of the discovery of AcrZ, there appears to be a crucial yet unexplored 
general role of small proteins for modulating activity of efflux pumps. For example, in 
muscle cells, a group of small proteins regulate calcium uptake by the SERCA pump 
(Anderson et al., 2015). In E. coli, KdpF is another small protein that increases the activity 
of a potassium transport protein (KdpFABC), while SgrT is a small protein that inhibits the 
glucose transport activity of EIICB (Storz et al., 2014). Structural studies of the role of 
these small proteins can further elucidate the different mechanisms of possible allosteric 
modulation. A number of other small proteins detected in E. coli  are also found at the 
membrane (Hemm et al., 2008), and we speculate that many of these proteins can act as 
allosteric modulators of target membrane protein partners.  
Accumulating evidence indicates that lipids can affect the localization, structure, 
stability and function of certain membrane proteins (Bechara et al., 2015; Gupta et al., 
2017; Laganowsky et al., 2014) (Renner and Weibel, 2011). Lipids have, for instance, 
been shown to directly regulate opening of the mechanosensitive channel MscS (Pliotas 
et al., 2015). E. coli aquaporin Z was found to be stabilised and functionally modulated 
by cardiolipin, and the E. coli ammonia channel AmtB was shown to selectivity bind 
phosphatidylglycerol (Laganowsky et al., 2014). Another study with co-polymer 
solubilized AcrB identified a pattern of lipid organization around the transmembrane 
portion (Qiu et al., 2018). We observe lipids in our maps as well, and our best model for 
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the AcrBZ complex with lipids is consistent with acyl chain packing and lipid head group 
interactions with AcrB observed in the other study (Fig 2).  
We structurally, computationally and functionally explored the impact of cardiolipin 
on AcrBZ. Taken together, our data suggest that the interaction of AcrZ and AcrB 
increases affinity of the complex for cardiolipin- and POPG-enriched environments inside 
the inner membrane. This effect does not appear to be due to the formation of specific 
interactions, but instead may originate from the greater surface for lipid contact in the 
presence of the AcrZ subunit (Appendix Fig S4). Cardiolipin and other lipids, together with 
AcrZ, modulate the activity of AcrB through allosteric changes – putatively by inducing 
structural alterations in the drug entry and binding sites. Our cryo-EM maps suggest that 
cardiolipin and AcrZ together also seem to encourage a more discrete binding mode for 
chloramphenicol in the AcrB distal pocket. This could be a reflection of, for example, an 
increased specificity for the drug when both regulators are present. The activities of other 
bacterial and mitochondrial membrane proteins have also been reported to be affected 
by interactions with cardiolipin (Dudek, 2017). Both a small protein and cardiolipin have 
been separately shown to promote the activity of MgtA, a magnesium importer in E. coli 
(Subramani et al., 2016; Wang et al., 2017a). Cardiolipin thus impacts processes ranging 
from electron transport to antimicrobial resistance by affecting protein localization, 
enhancing protein stability, mediating interactions between monomer units, and 
transmitting conformation changes between subunits (Dudek, 2017). Additionally, recent 
work has found that cardiolipin plays a role in proton motif force stimulation and 
modulation of ATPase activity in SecYEG (Corey et al., 2018). Cardiolipin also promotes 
the distribution of the osmosensory transporter ProP to the cellular poles in E. coli 
(Romantsov et al., 2007). Interestingly, in older bacterial cells, the AcrAB/TolC complex 
tends to cluster at the pole (Bergmiller et al., 2017), where it potentially could encounter 
a distinct lipid environment with impact on its function and activity. The recent studies of 
protein-lipid interactions, and cardiolipin in particular, shows the importance of continued 
study of membrane proteins in their native lipid environment. Knowledge of these 
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Figure Titles and Legends 
  
Figure 1.  E. coli AcrB and AcrBZ in saposin A discs.  
A  Structure of AcrB in saposin A discs prepared using E. coli lipids: Side (left; oriented 
so that the three-fold axis is aligned vertically), periplasmic (center; along the three-
fold axis), and cytoplasmic (right; along the three-fold axis) view. Within the trimer, the 
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AcrB subunits are found in loose (L, navy blue), tight (T, blue) and open (O, cyan blue) 
conformations. Two DARPin domains (yellow) are positioned at the top of the 
periplasmic domain; attached to protomers in loose (L) and tight (T) conformations.  
B  Refined model of AcrBZ fitted to the cryo-EM map in three views (see above). Two 
DARPin domains (yellow) are attached to protomers in L and T. AcrZ is displayed in 
red. 
 
Figure 2.  Organization and interactions of lipids in the central cavity of AcrB.  
A Left panel shows a view along the central axis of the AcrBZ complex with E. coli lipids 
at natural abundance. Right panel shows the cryo-EM density in the central region 
which reveals the hexagonal pattern for the lipids. Colours of AcrB subunits and AcrZ 
are the same as in Fig 1.  
B Snapshots of the lipid bilayer in the central cavity of AcrB at the end of a 500 ns 
simulation.  
C Average order parameters (Scd) of the palmitic (P) and vaccenic (V) acid lipid tails of 
PVPE in the outer and inner leaflets of the central cavity in two simulations (Sim1 and 
Sim2).  
D Hydrophobic residues that protrude into the outer leaflet of the lipid bilayer during the 
simulations in the different AcrB protomers, viewed perpendicular to the plane of the 
membrane (L, navy blue; T, blue; and O, cyan blue).  
 
Figure 3. Gallery of structural comparisons of AcrB and AcrBZ crystal structures 
(grey) overlaid by cryo-EM saposin A-nanodisc structures (coloured).  
A Overlay of protomers in L, T, O of (1) AcrB crystal structure (PDB-ID: 4DX5) (light 
grey; partially transparent) and (2) cryo-EM derived AcrB structure reconstituted in E. 
coli lipids inside a saposin A-nanodisc . Orientations of protomer overlays L, T, O in 
space were adjusted in depiction for a better display of observed changes. Colour 
Code: PC2, pink; PN2, purple; PC1, dark green; TMH 8, orange; TMH 4-6, navy blue; 
TMH 2, cyan blue; TMH 10-12, blue; I2, grey. Displayed are PC1/2, PN2, I2, TMH 2, 
TMH 8, TMH 10-12, and TMH 4-6 (i.e. reference frame), i.e. those section for which 
changes were visible.  
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B Overlay of protomers in L, T, O of (1) AcrBZ crystal structure (PDB-ID: 5NC5) (in grey; 
partially transparent) and (2) cryo-EM derived AcrBZ structure reconstituted in E. coli 
lipids inside a saposin A-nanodisc. The overlay was produced using MatchMaker 
command in Chimera using the rigid TMH 4-6 (blue) of AcrB crystal structure as 
reference frame. 
 
Figure 4. Impact of AcrZ curvature on binding to AcrB.  
A A snapshot of AcrZ bound to the AcrB in the loose conformation. The AcrZ is shown 
in tube representation and coloured based on the bending angle between its residues, 
from blue (0°) to red (30°), while the AcrB is shown in ribbon representation and 
coloured grey.  
B A zoom in of AcrZ bound to AcrB. AcrZ is oriented with the N terminus in the periplasm 
and the C terminus in the cytoplasm. The locations of P16 and A20 are indicated.  
C The evolution of the bending angle over the course of one of the simulations for all 
three AcrZ subunits. The conformation of AcrB (L, T, O) to which these AcrZ subunits 
are bound is shown on top left of each graph.  
D The sequence of AcrZ with residues mutated indicated in red.  
E Split adenylate cyclase two-hybrid assays of the interaction between plasmid-encoded 
T25-AcrB and the empty vector, wild type AcrZ-T18 or the indicated mutant. T25-AcrB 
and the AcrZ-T18 indicated were co-expressed in an adenylate cyclase deficient strain 
and grown to OD600 ~ 1 when cells were harvested for β-galactosidase activity assay. 
Shown are the average and standard deviation of three experiments.  The wt and 
vector samples are each shown twice.  
F Exponentially-growing cultures of the E. coli ∆acrZ strains carrying the pBAD24 empty 
vector, wild type AcrZ or the indicated AcrZ mutant were applied across 
chloramphenicol gradient plates to visualize differences in antibiotic sensitivity. The 
plates were incubated overnight at 37°C and photographed. Shown here is a 
representative image of an experiment carried out in triplicate. 
 
Figure 5. Cardiolipin biogenesis and AcrZ impact on chloramphenicol sensitivity.  
A Growth rates of E. coli MG1655 (wild type parent strain), MG1655 ∆acrZ, MG1655 
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∆clsABC::FRT-kan-FRT (cardiolipin-deficient) and MG1655 ∆clsABC::FRT-kan-FRT 
∆acrZ (cardiolipin-deficient and ∆acrZ) in the presence of a range of chloramphenicol 
(0 to 7 µg ml-1) and erythromycin (0 to 175 µg ml-1) concentrations were determined 
relative to the maximum growth rate in the absence of drug. OD660 measurements are 
presented as mean of triplicate measurements ± standard error of the mean. For the 
determination of the relative growth rates of the cultures in each of the wells, the 
exponential phase of the growth curve (as a mean of n = 3 for each culture type) was 
determined from the linear increase in a log10(OD660) versus time plot. The slope of 
this section was determined by simple linear regression. Heteroscedasticity-
consistent standard errors of the corresponding slope coefficient were calculated. The 
quality of the fit was significant in all cases (P < 0.05). Next, the relative growth rate 
was determined as the ratio of the growth rate in the presence of drug over the 
maximum growth rate in the absence of drug.  
B Exponentially-growing cultures of the above strains were applied across 
chloramphenicol or erythromycin gradient plates to visualize differences in antibiotic 
sensitivity. The plates were incubated overnight at 37°C and photographed. Shown is 
a representative gradient plate image of a biological replicate from experiments 
carried out for 10 different single colonies. The deletion of chromosomal acrZ results 
in a reproducible but slight increase in resistance to erythromycin in this E. coli strain 
background, but this mild effect is not observed in a different E. coli strain background 
(Hobbs et al 2012). 
 
Figure 6. Structural comparison between saposin A-disc reconstituted AcrB and 
AcrBZ with cardiolipin enrichment.  
Overlay of protomers in L, T, O of cryo-EM derived AcrB (in grey; partially transparent) 
reconstituted in E. coli lipids inside a saposin A-disc and AcrBZ (blue variants) 
reconstituted in E. coli lipids enriched with cardiolipin inside a saposin A-disc.  
A Channel 2 entry is restricted by a loop region of PC1/2 (light red) for substrate entry 
from the outer leaflet of the inner membrane in case of AcrB in L state but open in the 
case of the AcrBZ complex in L (dark red).  
B Once substrate enters the protomer in L, a switch loop (red) allows passage into the 
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deep-binding pocket in AcrB in complex with AcrZ. This loop appears to restrict access 
in case of the AcrB L protomer in the absence of AcrZ.  
C Impact on the drug binding pocket at the site of chloramphenicol binding. 
Chloramphenicol should be located inside the distal pocket of the AcrB in ‘tight’ 
conformation. Upon inspection of this area, no discernible chloramphenicol density 
could be identified, but the antibiotic is predicted to pack against residues P326, Y327, 
V139, F136, F610, F178, S135, I626, and V672 (red side chains). The residues are 
mostly on two sets of beta sheets in the porter domain of AcrB, as well as on nearby 
loops.  
D Cryo-EM density in the T state pocket for the AcrBZ complex with additional 
cardiolipin, showing the binding of chloramphenicol (grey) in a discrete conformation, 
with surrounding residues highlighted. Even though chloramphenicol or minocycline 
was added to other samples as well, density was not observed in this position for the 















STAR Methods  
 
LEAD CONTACT AND MATERIALS AVAILABILITY 
 
Further information and requests for resources and reagents should be directed to and 
will be fulfilled by the Lead Contact, Ben F. Luisi, bfl20@cam.ac.uk 
 




EXPERIMENTAL MODEL AND SUBJECT DETAILS 
 
Constructs of AcrB/DARPin and AcrBZ/DARPin complexes were previously described 
and grown in C43(DE3) acrab (Du et al., 2014; Eicher et al., 2012). Drug sensitivity assays 
used strain MG1655 ∆acrZ::km described earlier (Hobbs et al., 2012). Strain MG1655 
∆clsABC (cardiolipin-deficient) was kindly provided by Douglas B. Weibel (Oliver et al., 
2014). MG1655 ∆clsABC::FRT-kan-FRT ∆acrZ  (cardiolipin-deficient and ∆acrZ) was also 
used for drug sensitivity assays, and to prepare the  ∆acrZ ∆clsABC double mutation 
strain, the ∆acrZ::km allele was transduced from GSO213 (Hobbs et al., 2012) into 
MG1655 ∆clsABC strain following a standard P1 transduction protocol for E. coli genome 
manipulation (Thomason et al., 2007). MG1655 ∆acrZ (GSO284) was the background 
strain for all assays of acrZ mutants (Hobbs et al., 2010).  BTH101 was the background 
strain for the two-hybrid assays (Hobbs et al., 2012). E. coli shuffle-T7 cells were used to 
express human saposin A in LB medium containing carbenicillin (100 μg/ml).  
 
 
METHOD DETAILS  
 
 
Preparation of saposin A 
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Human saposin A was expressed in E. coli shuffle-T7 cells. Colonies of shuffle-
T7/pET15b-saposin A from a freshly transformed plate were used to inoculate 50 ml of 
LB medium containing carbenicillin (100 μg/ml) in a 250-ml baffled flask. The cells were 
grown in an orbital shaker at 30°C, 220 rpm overnight.  20 ml of the starter culture was 
used to inoculate 1000 ml LB medium (with carbenicillin) in a 2-l baffled flask at 30°C, 
220 rpm, and cultures were induced at A600=0.6 – 0.8 with 1 mM isopropyl 1-thio-b-D-
galactopyranoside (IPTG). The temperature was dropped to 16°C and the cells were 
grown at 220-rpm overnight. Cells were harvested by centrifugation at 4,200 rpm for 25 
min at 4°C. Cell pellets from a 2-l culture were resuspended in 50 ml AEX buffer (50 mM 
Tris-HCl, pH 7.4, 25 mM NaCl) with 1 tablet EDTA free protease inhibitor cocktail tablets 
and 5U/ml DNase I. Cells were lysed using a homogenizer (Emulsiflex) at 15,000 psi and 
the cell debris was pelleted by centrifugation at 40,000 xg for 30 min at 4°C. The 
supernatant was collected in a glass bottle, and was heat-treated at 85°C in a water bath 
for 10 min with gentle shaking, followed by centrifugation at 40,000 xg for 30 mins at 4°C. 
The supernatant was loaded onto a HiTrap Q column (GE Healthcare) equilibrated with 
AEX buffer.  The column was washed with 10 column volumes of AEX buffer and then 
saposin A was eluted over a 0 – 50% gradient of AEX elution buffer (20 mM Tris, pH 7.4, 
1 M NaCl). The fractions containing saposin A were pooled, and the protein was 
concentrated to 0.5 ml using 3 kDa Vivaspin concentrator. A final gel filtration step was 
performed using a Superdex 200 column equilibrated with GF Buffer-1 (20 mM HEPES 
pH 7.0, 150 mM NaCl). The peak fractions were concentrated, flash frozen in liquid 
nitrogen and stored at -80°C.   
 
Protein expression, purification and nanodisc reconstitution 
AcrB/DARPin and AcrBZ/DARPin complex purification followed the procedure described 
earlier (Du et al., 2014). The expression construct pET21a-acrB  His has the C-terminal 
histidines of AcrB substituted to prevent nonspecific association with the metal affinity 
matrix.  pET21a-acrBDHis and pRSFDuet-1-acrZHis5 were transformed into E. coli strain 
C43(DE3)   acrAB and cells were grown in 2xYT medium with 100 mg/ml carbenicillin 
and 50 mg/ml2 kanamycin at 37oC until the culture reached an absorbance, at 600nm, of 
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0.5–0.6 and was then induced by the addition of 0.5mMisopropyl 1-thio-b-D-
galactopyranoside (IPTG) at 18 oC overnight. Cell pellets were resuspended in lysis buffer 
(400mM NaCl, 20mM Tris-HCl, pH8.0) with 1 tablet per 50 ml EDTAfree protease inhibitor 
cocktail tablets, 5U/ml DNase I and 5mg/ml lysozyme, and the mixture was stirred at 4 oC 
for 1 h the passed 8 times through a homogenizer (EmulsiFlex) at 15,000 psi. Cell debris 
was removed by centrifugation at 9,000g for 30 min. Cellular membrane was pelleted by 
ultracentrifugation at 125,755g for 3 h, and pellets resuspended in lysis buffer with 
protease inhibitors and were solubilized by adding 1.5% DDM and stirring at 4oC for 3 h. 
Debris was pelleted by ultracentrifugation at 125,755g for 30 min. Imidazole was added 
to the membrane solution to a final concentration of 10mM. Histidine-tagged AcrBZ 
complex was purified by nickel affinity chromatography using a HiTrap chelating 
column (GE Healthcare Life Sciences) equilibrated with GF buffer 1 (400mM 
sodium chloride, 20mM Tris-HCl, pH 8.0, 0.05% DDM) containing 20mM imidazole. 
The column was washed with 50mM and 75mM imidazole added to GF 
buffer 1, respectively. Purified AcrBZ complex was eluted with 500mM imidazole 
in GF buffer 1, concentrated and loaded onto a Superose 6 column equilibrated 
with GF buffer 1. Fractions containing purified AcrBZ complex were pooled and 
concentrated to 15–20mg/ml using a Vivaspin concentrator(MWCO5100 kDa) 
and dialysed overnight against sample buffer (10mM HEPES pH7.5, 50mM NaCl, 
0.03%DDM) using a 100 kDa MWCO dialysis membrane to decrease the 
detergent concentration. Purified DARPin and AcrBZ complex were mixed at a molar ratio 
of 1:2 (AcrBZ monomer:DARPin monomer). The mixture was diluted with GF 
buffer 2 (20mM Tris-HCl, pH 7.5, 150mM NaCl, 0.03% DDM) to a 
concentration of 2–3 mg/ml, incubated at 4oC overnight, then concentrated to 
0.5ml using a Vivaspin concentrator (MWCO 100 kDa) and loaded onto a Superose 
6 column equilibrated withGF buffer 2. Fractions containing purified AcrBZ–DARPin 
complex were pooled and concentrated to 15–20mg/ml using a Vivaspin concentrator 
(MWCO 100 kDa) and dialysed overnight against sample buffer using 
a 100 kDaMWCO dialysis membrane; the final concentration was 10–15mg/ml.The 
purified, concentrated proteins were frozen in liquid nitrogen and stored at -80°C.  
 22 
Nanodiscs were reconstituted using a modification of a procedure described earlier 
(Frauenfeld et al., 2016).  Efficient nanodisc formation requires a step at pH 4, but AcrB 
and AcrBZ were unstable under this acidic condition. Thus, in the first step of the 
reconstitution procedures, nanodiscs were prepared with E. coli lipids at acidic pH and 
then brought to pH 7. In the second step, purified AcrB and AcrBZ were reconstituted into 
the pre-formed nanodiscs at the neutral pH.  
For lipid stock preparation, 20 mg of E. coli total lipid extract (Avanti) was dissolved 
in 0.5 ml of chloroform. For lipid stock with extra cardiolipin, 20 mg of E. coli total lipid 
extract and 1 ml of cardiolipin were mixed and dissolved in 0.5 ml of chloroform. The lipid 
solutions in glass vials were evaporated in a vacuum desiccator, then resuspended in 1 
ml of 50 mM HEPES pH 7.5, 150 mM NaCl and sonicated for 30 min. The lipid stocks 
were stored at -20°C.  For the nanodisc reconstitution, 28.2 µl of saposin A (4.484 mM) 
was mixed with 50.8 µl of E. coli lipid stock (25 mM; for cardiolipin-enriched nanodiscs, 
5% v/v purified cardiolipin (Avanti) was added to the lipid stock used for nanodisc 
formation), and then sodium acetate (50 mM pH:4.8) was added to the mixture to a final 
volume of 500 µl and incubated at 37°C for 10 min. 1 ml of GF buffer-2 (Tris 20 mM pH 
7.5, NaCl 150 mM) was added to the mixture, and the buffer was exchanged to GF Buffer-
2 using a HiTrap Desalting 5 ml column. 2 ml of the eluate was mixed with AcrB/DARPin 
or AcrBZ/DARPin. The molar ratio of AcrB/DARPin or AcrBZ/DARPin:saposin A:lipid is 
about 1:10:100 in the reconstitution. The mixture was incubated at 4°C for half an h and 
dialyzed against 1000 ml of GF Buffer-2 overnight. The sample was dialyzed again 
against 1000 ml of GF Buffer-2 for further 3 h. The buffer exchanged sample was 
concentrated to 500 µl and purified by gel filtration chromatography using a Superdex 200 
column equilibrated with GF Buffer-2. The peak fractions containing the protein in 
nanodiscs were concentrated to 2 mg/ml. Minocycline was added to AcrB/nanodisc or 
AcrB/nanodisc-cardiolipin to a final concentration of 2 mM; Chloramphenicol was added 
to AcrBZ/nanodisc or AcrBZ/nanodisc-cardiolipin to 1 mM. The mixtures were incubated 
for 1 h at 4°C, then flash frozen in liquid nitrogen and stored at -80°C.  
 
Electron cryo-microscopy  
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For the structure determination of saposin A discs with AcrB and AcrBZ as well as both 
complexes with supplementary cardiolipin, a 4.0 µl aliquot at 2 mg/ml was applied onto 
holey carbon film supported by a 300-mesh R1.2/1.3 Quantifoil gold grid (Quantifoil) that 
had been previously glow discharged. The grid was blotted for 2.5 – 3.0 seconds and 
rapidly frozen in liquid ethane using a Vitrobot IV (FEI) at 4°C and 100% humidity. The 
grids were stored in liquid nitrogen before imaging. Zero-energy-loss images of frozen-
hydrated AcrB disc particles were recorded automatically on an FEI Titan Krios electron 
microscope at 300 kV, using a slit width of 20 eV on a GIF Quantum energy filter and a 
Gatan K2-Summit direct electron detector (Gatan) in counting mode. Images of frozen-
hydrated AcrB/nanodisc-cardiolipin, AcrBZ/nanodisc and AcrBZ/nanodisc-cardiolipin 
particles were acquired automatically on the FEI Titan Krios electron microscope at 300 
kV using a Falcon III direct electron detector camera (FEI) in counting mode.  
 
Image processing and 3D reconstruction 
The software MotionCor2 (Zheng et al., 2017) was used for whole-frame motion 
correction and dose weighting, Gctf (Zhang, 2016) for estimation of the contrast transfer 
function parameters, and RELION-3.0 (Scheres, 2012) package for all other image 
processing steps. A particle subset was manually selected to calculate reference-free 2D 
class averages, which was then used as templates for automated particle picking of the 
entire data set. The templates were low-pass filtered to 20 Å to limit model bias. Then 
several runs of 2D classifications were used to remove the heterogeneous particles, as 
well as the false positive particles from the auto-picking. A reference map was generated 
from crystal structure of AcrB using a program pdb2mrc in the EMAN package (Ludtke et 
al, 1999), and was low pass filtered to 60 Å resolution and was used as a starting point 
for the 3D classification. We selected good particles for further analysis based on the 
quality and high resolution in the 2D and 3D classification. The 3D auto-refinement 
resulted in near-atomic resolution maps. After per-particle motion correction and 
radiation-damage weighting by Bayesian polishing in RELION (Zivanov et al, 2018), the 
polished particles were subjected to 2D and 3D classifications, and 3D auto-refinement 
again. A soft mask in RELION post-processing was applied before computing the FSCs. 
The overall resolution of the maps was estimated by the gold-standard FSC criterion with 
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0.143 cut-off (Henderson and Rosenthal, 2003). Local resolution variations were 
estimated with ResMap (Kucukelbir et al, 2014). The data collection and processing 
parameters for all four specimens are summarized in Table S1.  
 
Model docking and refinement 
Automated structural refinement using Rosetta followed the procedure described in 
(Wang et al., 2017b). The models were refined with PHENIX (Adams et al., 2010; 
Liebschner et al., 2019) and ISOLDE (Croll, 2018), and the structures were further 
modelled and visualized using PyMOL (DeLano, 2002), Chimera (Pettersen et al., 2004) 
and Coot (Emsley et al., 2010). The crystal structure of human saposin A in the open 
state was docked into the maps. Density was also apparent for lipids, and the 
corresponding hydrocarbon portion was modelled into the density where there was good 
correspondence. Although the AcrB/nanodisc specimens were prepared in the presence 
of minocycline, density for the compound was not apparent in the refined cryo-EM maps 
inside the periplasmic domain. However, weak density that is consistent with minocycline 
is present near F556 (subunit A). A more defined density was found in the 
AcrBZ/nanodisc-cardiolipin EM map and subsequently assigned to chloramphenicol, 
which was added to the sample prior to freezing. The quality of the stereochemistry was 
evaluated with EMRinger (Barad et al., 2015) and MOLPROBITY (Chen et al., 2010).   
 
Molecular dynamics simulations 
For the atomistic simulations, the proteins were parameterized using CHARMM36 force 
field (Huang and MacKerell Jr, 2013), whilst the parameters for the antibiotic 
chloramphenicol were obtained using CHARMM-GUI ligand modeler (Kim et al., 2017). 
The AcrZ P16A M19P mutant was generated using PyMOL (DeLano, 2002). A small 
patch of 15 X 15 nm model membrane was constructed using CHARMM-GUI membrane 
builder (Jo et al., 2009) to mimic the lipid composition of Escherichia coli K12 inner 
membrane (Aibara et al., 1972; Lugtenberg and Peters, 1976; Yokota et al., 1980) (75% 
1-palmitoyl 2-cis-vaccenic phosphatidylethanolamine (PVPE), 20% 1-palmitoyl 2-cis-
vaccenic phosphatidylglycerol (PVPG) and 5% 1-palmitoyl 2-cis-vaccenic 3-palmitoyl 4-
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cis-vaccenic diphosphatidylglycerol (cardiolipin)). Protein insertion into the membrane 
was performed using the g_membed protocol in GROMACS (Wolf et al., 2010). This 
system was then solvated with the SPC water molecules (Lins and Hünenberger, 2005) 
and neutralised with 0.15 M NaCl. A short 1 ns equilibration simulation was performed 
whereby the heavy atoms of the protein were positionally restrained using a force 
constant of 1000 kJ mol-1. The temperature was kept at 310 K using the Nose-Hoover 
thermostat with a time constant of 1.0 ps (Hoover, 1985; Nosé, 1984).  The pressure was 
held at 1 atm using a semi-isotropic coupling to the Parrinello-Rahman barostat with a 
time constant of 1.0 ps (Parrinello and Rahman, 1981b). The electrostatic interactions 
were calculated using the smooth particle mesh Ewald method with a real-space cut off 
value of 1.2 nm (Essmann et al., 1995). The twin range cut-off method with a cut-off value 
of 1.2 nm was used to calculate the Van der Waals interactions, whereby the forces were 
switched to zero between 1.0 to 1.2 nm. The LINCS algorithm was utilised to constrain 
all covalent bonds to their equilibrium value, allowing for a 2 fs time step (Hess et al., 
1997). After this equilibration simulation, the position restrains on the protein were 
removed and two independent production runs, each for 500 ns, were conducted with 
different starting velocities. Steered molecular dynamic simulations were performed 
whereby a harmonic spring with a force constant of 100 kJ mol-1 nm-2 was attached to the 
center of mass of chloramphenicol and pulled at a constant velocity of 0.1 nm ns-1 towards 
a reference residue (F136) found in the deep binding pocket of the L protomer. Three 
independent steered molecular dynamic simulations were performed for each of AcrB and 
AcrBZ starting with different velocities. 
For the coarse-grained simulations, the proteins were converted to coarse-grained 
representation using the martinize.py script using the MARTINI 2.2 force field (Monticelli 
et al., 2008) with ElNeDyn to retain the secondary and tertiary structures (Periole et al., 
2009). A patch of 30 x 30 nm membrane model of the same lipid composition as the 
atomistic simulation was constructed using CHARMM-GUI Martini Maker Bilayer Builder 
(Qi et al., 2015). The protein was placed in the middle of the membrane and overlapping 
lipids were removed. To understand the interactions between the protein and charged 
lipids, we reorganized the position of POPG and cardiolipin such that at the beginning of 
the simulation there were none of these lipids within 30 Å of the protein. The simulation 
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box was solvated with the standard MARTINI water molecules and neutralised with 0.15 
M NaCl. Energy minimisation was then performed using the steepest descent method. 
The system was subsequently equilibrated for 10 ns with positional restrains applied on 
the protein. The temperature was maintained at 310 K using a velocity-rescaling 
thermostat (Bussi et al., 2007), with a relaxation time of 1 ps, whereas the pressure was 
maintained at 1 bar by a semi-isotropic coupling with the Berendsen barostat (Berendsen 
et al., 1984) and a time constant of 5 ps. The cut-off for the nonbonded interactions was 
set at a distance of 1.2 nm, while the Lennard-Jones and Coulomb potentials were shifted 
from 0.9 and 0.0 to the cut-off distance, respectively. The LINCS algorithm was used to 
constrain all covalent bonds to their equilibrium values (Hess et al., 1997) and the time 
step was slightly increased from 2, 5, 8 to 10 fs to allow the system to be well equilibrated. 
After the equilibration simulations, protein position restraints were removed and three 
independent production runs with different starting velocities were performed for 5 μs 
using the same parameters, except a Parrinello-Rahman barostat with a time constant of 
12 ps was used to control the pressure (Parrinello and Rahman, 1981a). 
 All simulations were performed using the GROMACS 5 package (Abraham et al., 
2015) and visualised in VMD (Humphrey et al., 1996). The bending angle of AcrZ was 
determined using the Bendix plug-in within VMD (Dahl et al., 2012). Protein-lipid contact 
analysis was performed using gmx select. The partial mass density landscapes was 
generated with a modified version of the g_density tool (Castillo et al., 2013). 
 
Bacterial two-hybrid assays 
Single colonies of a E. coli strain adenylate cyclase deletion strain (BTH101) freshly 
transformed with plasmids bearing acrZ fused to the T18 fragment of adenylate cyclase 
on the C-terminus and acrB fused to the T25 fragment of adenylate cyclase on the N-
terminus were grown in 1 ml of LB medium supplemented with 30 µg/ml kanamycin and 
50 µg/ml carbenicillin at 37°C with shaking at 250 rpm overnight. The cultures were diluted 
1:100 into 3 ml of the same medium also containing 1 mM IPTG inducer and were similarly 
grown to OD600 ~ 1. An aliquot of sample was used for β-galactosidase assays as 
previously described (Miller, 1992) with some modifications. The OD600 was recorded and 
a 100 µl aliquot was added to a 1.5 ml microfuge tube containing 700 µl Z buffer (60 mM 
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Na2HPO4, 40 mM NaH2PO4, 10 mM KCl, 1 mM MgSO4, 2.7 µl/ml of β-mercaptoethanol, 
1.5 µl/ml of 0.1% SDS) and 30 µl chloroform. The samples were vortexed and incubated 
for 15 min at 28°C, whereupon 100 µl of 8 mg/ml ortho-nitrophenyl-β-galactoside (ONPG) 
in Z buffer was added to the sample and vortexed and returned to 28°C. Once a yellow 
colour developed (~10 min), 0.5 ml of 1 M Na2CO3 was added and the sample was 
vortexed. The start times (addition of ONPG) and the stop times (addition of Na2CO3) 
were recorded. The sample was centrifuged to remove pellet debris and the A420 of the 
supernatant was recorded. Miller Units were calculated as follows: (1000 × A420) ÷ (t × v 
× OD600), where t is min and v is ml. 
 
Gradient plate assay 
Gradient plates were prepared as previously described (Bryson and Szybalski, 1952) with 
slight modifications. In brief, a 100 mm x 100 mm x 1.5 mm square petri dish (Thomas 
Scientific) was propped up on a 1 cm ledge to create a slant. 40 ml of LB with 1.5% agar 
and either 10 µg/ml chloramphenicol or 300 µg/ml erythromycin was poured and allowed 
to harden. The plate was then laid flat and 40 ml of LB with 1.5% agar was overlaid. For 
strains carrying plasmids, both top and bottom agar were also supplemented with 50 
µg/ml carbenicillin and 0.02% arabinose. Colonies for each strain isolated from sterile LB-
Agar plates were grown overnight in LB (with carbenicillin for plasmid-containing strains) 
at 37°C with shaking at 250 rpm. The overnight cultures were diluted 1:100 and grown in 
the same media at 37°C with shaking at 250 rpm to exponential phase (OD600~0.4). 
Aliquots (15 µl) were dripped down the plate starting from the edge with the lowest 
antibiotic concentration. The drips were allowed to dry, and the plates were incubated at 
37°C for 16 h and imaged using the fluorescein setting on a ChemiDoc MP Imaging 
machine (Biorad). Each gradient plate assayed cultures generated from separate single 
colonies. Reproducible results were observed for 10 gradient plate assays conducted 
over three separate days. A representative image was selected for publication.  
 
Cell growth for drug sensitivity assay 
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Colonies from E. coli MG1655 (wild type parent strain), MG1655 ∆acrZ, MG1655 
∆clsABC::FRT-kan-FRT (cardiolipin-deficient) and MG1655 ∆clsABC::FRT-kan-FRT 
∆acrZ (cardiolipin-deficient and ∆acrZ) isolated from sterile LB-Agar plates were grown in 
LB for about 3 h at 37°C and then used to inoculate fresh medium in a 96-well plate. The 
cells were diluted to OD600nm ~0.06 in fresh LB medium in the wells of a 96-well plate to 
which antibiotics were added as indicated in Fig 5. Growth was followed over time at 
OD660 at 37°C in a CLARIOstar microplate reader (BMG LABTECH). For the 
determination of the relative growth rates of the cultures in each of the wells, the 
exponential phase of the growth curve (as a mean of n = 3 for each culture type) was 
determined from the linear increase in a log10(OD660nm) versus time plot. The slope of this 
section was determined by simple linear regression. Heteroscedasticity-consistent 
standard errors of the corresponding slope coefficient were calculated. The quality of the 
fit was significant in all cases (P < 0.05). Next, the relative growth rate was determined 
as the ratio of the growth rate in the presence of drug over the maximum growth rate in 
the absence of drug.  
 
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
 
Statistical analyses of data are described in the legends for Figures 4E,F and 5A 
 
DATA AND CODE AVAILABILITY 
The cryoEM maps and models are available in the PDB and EMDB databases with 
codes, respectively of 6SGS and 10183 for the AcrBZ/saposin A disc with 
chloramphenicol; 6SGU and 10185 for AcrB/saposin A disc with minocycline; 6SGR and 
10182 for AcrBZ/saposin A disk with 5% cardiolipin and chloramphenicol; and 6SGT 
and 10184 for AcrB/saposin A disc with 5% cardiolipin and minocycline. 
 
Table S2 provides root mean square fits in angstrom for pairwise comparisons of the 






Abraham, M.J., Murtola, T., Schulz, R., Páll, S., Smith, J.C., Hess, B., and Lindahl, E. 
(2015). GROMACS: High performance molecular simulations through multi-level 
parallelism from laptops to supercomputers. SoftwareX 1, 19-25. 
 
Adams, P.D., Afonine, P.V., Bunkóczi, G., Chen, V.B., Davis, I.W., Echols, N., Headd, 
J.J., Hung, L.-W., Kapral, G.J., and Grosse-Kunstleve, R.W. (2010). PHENIX: a 
comprehensive Python-based system for macromolecular structure solution. Acta 
Crystallogr D Biol Crystallogr 66, 213-221. 
 
Aibara, S., Kato, M., Ishinaga, M., and Kito, M. (1972). Changes in positional distribution 
of fatty acids in the phospholipids of Escherichia coli after shift-down in temperature. 
Biochim Biophys Acta 270, 301-306. 
 
Anderson, D.M., Anderson, K.M., Chang, C.-L., Makarewich, C.A., Nelson, B.R., 
McAnally, J.R., Shelton, J.M., Liou, J., Bassel-Duby, R., and Olson, E.N. (2015). 
Regulation of muscle contractility by a family of SERCA-inhibitory micropeptides. Cell 
160, 595-606. 
 
Barad, B.A., Echols, N., Wang, R.Y.-R., Cheng, Y., DiMaio, F., Adams, P.D., and Fraser, 
J.S. (2015). EMRinger: side chain–directed model and map validation for 3D cryo-
electron microscopy. Nat Methods 12, 943. 
 
Bechara, C., Nöll, A., Morgner, N., Degiacomi, M.T., Tampé, R., and Robinson, C.V. 
(2015). A subset of annular lipids is linked to the flippase activity of an ABC transporter. 
Nat Chem 7, 255-262. 
 
Berendsen, H.J., van Postma, J., van Gunsteren, W.F., DiNola, A., and Haak, J. (1984). 
Molecular dynamics with coupling to an external bath. J Chem Phys 81, 3684-3690. 
 30 
Bergmiller, T., Andersson, A.M., Tomasek, K., Balleza, E., Kiviet, D.J., Hauschild, R., 
Tkačik, G., and Guet, C.C. (2017). Biased partitioning of the multidrug efflux pump AcrAB-
TolC underlies long-lived phenotypic heterogeneity. Science 356, 311-315. 
 
Bryson, V., and Szybalski, W. (1952). Microbial selection. Science 116, 45-51. 
Bussi, G., Donadio, D., and Parrinello, M. (2007). Canonical sampling through velocity 
rescaling. J Chem Phys 126, 014101. 
 
Castillo, N., Monticelli, L., Barnoud, J., and Tieleman, D.P. (2013). Free energy of 
WALP23 dimer association in DMPC, DPPC, and DOPC bilayers. Chem Phys Lipids 169, 
95-105. 
 
Chen, V.B., Arendall, W.B., Headd, J.J., Keedy, D.A., Immormino, R.M., Kapral, G.J., 
Murray, L.W., Richardson, J.S., and Richardson, D.C. (2010). MolProbity: all-atom 
structure validation for macromolecular crystallography. Acta Crystallogr D Biol 
Crystallogr 66, 12-21. 
 
Chorev, D.S., Baker, L.A., Wu, D., Beilsten-Edmands, V., Rouse, S.L., Zeev-Ben-
Mordehai, T., Jiko, C., Samsudin, F., Gerle, C., and Khalid, S. (2018). Protein assemblies 
ejected directly from native membranes yield complexes for mass spectrometry. Science 
362, 829-834. 
 
Corey, R.A., Pyle, E., Allen, W.J., Watkins, D.W., Casiraghi, M., Miroux, B., Arechaga, I., 
Politis, A., and Collinson, I. (2018). Specific cardiolipin–SecY interactions are required for 
proton-motive force stimulation of protein secretion. Proc Natl Acad Sci USA 115, 7967-
7972. 
 
Croll, T.I. (2018). ISOLDE: a physically realistic environment for model building into low-
resolution electron-density maps. Acta Crystallogr D Struct Biol 74, 519-530. 
 
 31 
Dahl, A.C.E., Chavent, M., and Sansom, M.S. (2012). Bendix: intuitive helix geometry 
analysis and abstraction. Bioinformatics 28, 2193-2194. 
 
DeLano, W.L. (2002). The PyMOL molecular graphics system. http://www.pymol.org. 
 
Denisov, I.G., and Sligar, S.G. (2016). Nanodiscs for structural and functional studies of 
membrane proteins. Nat Struct Mol Biol 23, 481-486. 
 
Dowhan, W. (1997). Molecular basis for membrane phospholipid diversity: why are there 
so many lipids? Annu Rev Biochem 66, 199-232. 
 
Du, D., Wang, Z., James, N.R., Voss, J.E., Klimont, E., Ohene-Agyei, T., Venter, H., Chiu, 
W., and Luisi, B.F. (2014). Structure of the AcrAB-TolC multidrug efflux pump. Nature 
509, 512-515. 
 
Dudek, J. (2017). Role of cardiolipin in mitochondrial signaling pathways. Front Cell Dev 
Biol 5, 90. 
 
Eicher, T., Cha, H.-j., Seeger, M.A., Brandstätter, L., El-Delik, J., Bohnert, J.A., Kern, 
W.V., Verrey, F., Grütter, M.G., and Diederichs, K. (2012). Transport of drugs by the 
multidrug transporter AcrB involves an access and a deep binding pocket that are 
separated by a switch-loop. Proc Natl Acad Sci USA 109, 5687-5692. 
 
Emsley, P., Lohkamp, B., Scott, W.G., and Cowtan, K. (2010). Features and development 
of Coot. Acta Crystallogr D Biol Crystallogr 66, 486-501. 
 
Essmann, U., Perera, L., Berkowitz, M.L., Darden, T., Lee, H., and Pedersen, L.G. (1995). 
A smooth particle mesh Ewald method. J Chem Phys 103, 8577-8593. 
 
 32 
Frauenfeld, J., Löving, R., Armache, J.P., Sonnen, A.F., Guettou, F., Moberg, P., Zhu, L., 
Jegerschöld, C., Flayhan, A., Briggs, J.A., et al. (2016). A saposin-lipoprotein nanoparticle 
system for membrane proteins. Nat Methods 13, 345-351. 
 
Gupta, K., Donlan, J.A., Hopper, J.T., Uzdavinys, P., Landreh, M., Struwe, W.B., Drew, 
D., Baldwin, A.J., Stansfeld, P.J., and Robinson, C.V. (2017). The role of interfacial lipids 
in stabilizing membrane protein oligomers. Nature 541, 421-424. 
 
Guzman, L.M., Belin, D., Carson, M.J., and Beckwith J. (1995) Tight regulation, 
modulation, and high-level expression by vectors containing the arabinose PBAD 
promoter. J. Bacteriol. 177, 4121-30. 
 
Hemm, M.R., Paul, B.J., Schneider, T.D., Storz, G., and Rudd, K.E. (2008). Small 
membrane proteins found by comparative genomics and ribosome binding site models. 
Mol Microbiol 70, 1487-1501. 
 
Hess, B., Bekker, H., Berendsen, H.J., and Fraaije, J.G. (1997). LINCS: a linear constraint 
solver for molecular simulations. J Comput Chem 18, 1463-1472. 
 
Hobbs, E.C., Astarita, J.L., and Storz, G. (2010). Small RNAs and small proteins involved 
in resistance to cell envelope stress and acid shock in Escherichia coli: analysis of a bar-
coded mutant collection. J Bacteriol 192, 59-67. 
 
Hobbs, E.C., Yin, X., Paul, B.J., Astarita, J.L., and Storz, G. (2012). Conserved small 
protein associates with the multidrug efflux pump AcrB and differentially affects antibiotic 
resistance. Proc Natl Acad Sci USA 109, 16696-16701. 
 
Hobson, J.J., Gallegos, A.S., Atha III, B.W., Kelly, J.P., Lein, C.D., VanOrsdel, C.E., 
Weldon, J.E., and Hemm, M.R. (2018). Investigation of amino acid specificity in the CydX 
small protein shows sequence plasticity at the functional level. PLoS One 13, e0198699. 
 33 
Hoover, W.G. (1985). Canonical dynamices: Equilibrium phase-space distributions. Phys 
Rev A Gen Phys 31, 1695-1697. 
 
Huang, J., and MacKerell Jr, A.D. (2013). CHARMM36 all-atom additive protein force 
field: Validation based on comparison to NMR data. J Comput Chem 34, 2135-2145. 
Humphrey, W., Dalke, A., and Schulten, K. (1996). VMD: visual molecular dynamics. J 
Mol Graph 14, 33-38. 
 
Jeong, H., Kim, J.-S., Song, S., Shigematsu, H., Yokoyama, T., Hyun, J., and Ha, N.-C. 
(2016). Pseudoatomic structure of the tripartite multidrug efflux pump AcrAB-TolC reveals 
the intermeshing cogwheel-like interaction between AcrA and TolC. Structure 24, 272-
276. 
 
Jo, S., Lim, J.B., Klauda, J.B., and Im, W. (2009). CHARMM-GUI Membrane Builder for 
mixed bilayers and its application to yeast membranes. Biophys J 97, 50-58. 
 
Kim, S., Lee, J., Jo, S., Brooks III, C.L., Lee, H.S., and Im, W. (2017). CHARMM-GUI 
ligand reader and modeler for CHARMM force field generation of small molecules. J 
Comput Chem 38, 1879-1886. 
 
Laganowsky, A., Reading, E., Allison, T.M., Ulmschneider, M.B., Degiacomi, M.T., 
Baldwin, A.J., and Robinson, C.V. (2014). Membrane proteins bind lipids selectively to 
modulate their structure and function. Nature 510, 172-175. 
 
Liebschner, D., Afonine, P.V., Baker, M.L., Bunkóczi, G., Chen, V.B., Croll, T.I., Hintze, 
B., Hung, L.-W., Jain, S., McCoy, A.J., Moriarty, N.W., Oeffner, R.D., Poon, B.K.,  Prisant, 
M.G., Read, R.J., Richardson, J.S., Richardson, D.C., Sammito, M.D, Sobolev, O.V., 
Stockwell, H.D., Terwilliger, T.C., Urzhumtsev, A.G., Videau, L.L., Williams, C.J. and  
Adams, P.D. Acta Cryst. (2019). D75, 861-877. 
 
 34 
Lins, R.D., and Hünenberger, P.H. (2005). A new GROMOS force field for hexopyranose-
based carbohydrates. J Comput Chem 26, 1400-1412. 
 
Lugtenberg, E., and Peters, R. (1976). Distribution of lipids in cytoplasmic and outer 
membranes of Escherichia coli K12. Biochim Biophys Acta 441, 38-47. 
 
Miller, J.H. (1992). A short course in bacterial genetics : a laboratory manual and 
handbook for Escherichia coli and related bacteria (New York (N.Y.) : Cold Spring Harbor 
laboratory press). 
 
Monticelli, L., Kandasamy, S.K., Periole, X., Larson, R.G., Tieleman, D.P., and Marrink, 
S.-J. (2008). The MARTINI coarse-grained force field: extension to proteins. J Chem 
Theory Comput 4, 819-834. 
 
Murakami, S., Nakashima, R., Yamashita, E., Matsumoto, T., and Yamaguchi, A. (2006). 
Crystal structures of a multidrug transporter reveal a functionally rotating mechanism. 
Nature 443, 173-179. 
 
Nosé, S. (1984). A unified formulation of the constant temperature molecular dynamics 
methods. J Chem Phys 81, 511-519. 
 
Oliver, P.M., Crooks, J.A., Leidl, M., Yoon, E.J., Saghatelian, A., and Weibel, D.B. (2014). 
Localization of anionic phospholipids in Escherichia coli cells. J Bacteriol 196, 3386-3398. 
 
Parrinello, M., and Rahman, A. (1981a). Polymorphic transitions in single crystals: A new 
molecular dynamics method. Journal of Applied physics 52, 7182-7190. 
 
Parrinello, M., and Rahman, A. (1981b). Polymorphic transitions in single crystals: A new 
molecular dynamics method. J Appl Phys 52, 7182-7190. 
 
 35 
Periole, X., Cavalli, M., Marrink, S.-J., and Ceruso, M.A. (2009). Combining an elastic 
network with a coarse-grained molecular force field: structure, dynamics, and 
intermolecular recognition. J Chem Theory Comput 5, 2531-2543. 
 
Pettersen, E.F., Goddard, T.D., Huang, C.C., Couch, G.S., Greenblatt, D.M., Meng, E.C., 
and Ferrin, T.E. (2004). UCSF Chimera—a visualization system for exploratory research 
and analysis. J Comput Chem 25, 1605-1612. 
 
Pliotas, C., Dahl, A.C.E., Rasmussen, T., Mahendran, K.R., Smith, T.K., Marius, P., Gault, 
J., Banda, T., Rasmussen, A., and Miller, S. (2015). The role of lipids in 
mechanosensation. Nat Struct Mol Biol 22, 991. 
Qi, Y., Ingólfsson, H.I., Cheng, X., Lee, J., Marrink, S.J., and Im, W. (2015). CHARMM-
GUI martini maker for coarse-grained simulations with the martini force field. J Chem 
Theory Comput 11, 4486-4494. 
 
Qiu, W., Fu, Z., Xu, G.G., Grassucci, R.A., Zhang, Y., Frank, J., Hendrickson, W.A., and 
Guo, Y. (2018). Structure and activity of lipid bilayer within a membrane-protein 
transporter. Proc Natl Acad Sci USA 115, 12985-12990. 
 
Renner, L.D., and Weibel, D.B. (2011). Cardiolipin microdomains localize to negatively 
curved regions of Escherichia coli membranes. Proc Natl Acad Sci USA 108, 6264-6269. 
 
Romantsov, T., Helbig, S., Culham, D.E., Gill, C., Stalker, L., and Wood, J.M. (2007). 
Cardiolipin promotes polar localization of osmosensory transporter ProP in Escherichia 
coli. Mol Microbiol 64, 1455-1465. 
 
Scheres, S.H. (2012). RELION: implementation of a Bayesian approach to cryo-EM 
structure determination. J Struct Biol 180, 519-530. 
 
 36 
Seeger, M.A., Schiefner, A., Eicher, T., Verrey, F., Diederichs, K., and Pos, K.M. (2006). 
Structural asymmetry of AcrB trimer suggests a peristaltic pump mechanism. Science 
313, 1295-1298. 
 
Sennhauser, G., Amstutz, P., Briand, C., Storchenegger, O., and Grütter, M.G. (2006). 
Drug export pathway of multidrug exporter AcrB revealed by DARPin inhibitors. PLoS Biol 
5, e7. 
 
Storz, G., Wolf, Y.I., and Ramamurthi, K.S. (2014). Small proteins can no longer be 
ignored. Annu Rev Biochem 83, 753-777. 
 
Subramani, S., Perdreau-Dahl, H., and Morth, J.P. (2016). The magnesium transporter A 
is activated by cardiolipin and is highly sensitive to free magnesium in vitro. eLife 5, pii: 
e11407. 
 
Thomason, L.C., Costantino, N., and Court, D.L. (2007). E. coli genome manipulation by 
P1 transduction. Curr Protoc Mol Biol 79, 1.17. 11-11.17. 18. 
 
Wang, H., Yin, X., Wu Orr, M., Dambach, M., Curtis, R., and Storz, G. (2017a). Increasing 
intracellular magnesium levels with the 31-amino acid MgtS protein. Proc Natl Acad Sci 
USA 114, 5689-5694. 
 
Wang, Z., Fan, G., Hryc, C.F., Blaza, J.N., Serysheva, I.I., Schmid, M.F., Chiu, W., Luisi, 
B.F., and Du, D. (2017b). An allosteric transport mechanism for the AcrAB-TolC multidrug 
efflux pump. eLife 6, e24905. 
 
Wolf, M.G., Hoefling, M., Aponte-Santamaría, C., Grubmüller, H., and Groenhof, G. 
(2010). g_membed: Efficient insertion of a membrane protein into an equilibrated lipid 
bilayer with minimal perturbation. J Comput Chem 31, 2169-2174. 
 
 37 
Yokota, K., Kanamoto, R., and Kito, M. (1980). Composition of cardiolipin molecular 
species in Escherichia coli. J Bacteriol 141, 1047-1051. 
 
Zheng, S.Q., Palovcak, E., Armache, J.-P., Verba, K.A., Cheng, Y., and Agard, D.A. 
(2017). MotionCor2: anisotropic correction of beam-induced motion for improved cryo-
electron microscopy. Nat Methods 14, 331. 
 
Zwama, M., and Yamaguchi, A. (2018). Molecular mechanisms of AcrB-mediated 
















































KEY RESOURCES TABLE 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Bacterial and Virus Strains  
Escherichia coli adenylate cyclase deletion strain 
BTH101 
Euromedex N/A 
E. coli MG1655 (wild type parent strain) Storz laboratory N/A 
E. coli MG1655 ∆acrZ This study N/A 
E. coli MG1655 ∆clsABC::FRT-kan-FRT  
(cardiolipin-deficient) 
Douglas B. Weibel N/A 
E. coli MG1655 ∆clsABC::FRT-kan-FRT ∆acrZ 
(cardiolipin-deficient and ∆acrZ) 
This study N/A 
E. coli shuffle-T7 New England Biolabs C3029J 
   
Chemicals, Peptides, and Recombinant Proteins 
E.coli lipid extract Avanti 100500 
cardiolipin Avanti 841199 
Ortho-nitrophenyl-beta-galactoside (ONPG) Sigma N1127-5G 
Critical Commercial Assays 
   
   
Deposited Data 
AcrB in complex with AcrZ in saposin A disk and 
chloramphenicol 
This study PDB 6SGS  
EMDB 10183 
AcrB in complex with AcrZ in saposin A disk + 
supplementary cardiolipin and chloramphenicol 
This study PDB 6SGR 
EMDB 10182 
AcrB saposin A disk and minocycline This study PDB 6SGU 
EMDB 10185 
AcrB saposin A disk + supplementary cardiolipin and 
minocycline 
This study PDB 6SGT 
EMDB 10184 
AcrB with DARPin in detergent Eicher et al., 2012 PDB 4DX5 
AcrB in complex with AcrZ and puromycin in detergent Wang et al., 2017 PDB 5NC5 
AcrB in complex with AcrZ in deterget Du et al., 2014 PDB 4CDI 
   
Oligonucleotides                                                                                         see Table S3 
Recombinant DNA 
pBAD24, arabinose-inducible expression vector Guzman et al., 1995  N/A 
pBAD24-acrZ from Escherichia coli MG1655 (GeneID: 
945365) cloned into EcoRI and HindII sites Hobbs et al., 2012  N/A 
pBAD24-acrZ P16A This study N/A 
pBAD24-acrZ P16A V17P This study N/A 
pBAD24-acrZ P16A V18P This study N/A 
pBAD24-acrZ P16A M19P This study N/A 
pBAD24-acrZ P16A A20P This study N/A 
pBAD24-acrZ M19P This study N/A 
pBAD24-acrZ A20P This study N/A 
pBAD24-acrZ P16G This study N/A 
pBAD24-acrZ V15G P16G This study N/A 
pBAD24-acrZ P16G V17G This study N/A 
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pBAD24-acrZ S7A This study N/A 
pBAD24-acrZ V15A This study N/A 
pBAD24-acrZ M19A This study N/A 
pBAD24-acrZ I22A This study N/A 
pBAD24-acrZ L23A This study N/A 
pBAD24-acrZ I26A This study N/A 
pBAD24-acrZ L29A This study N/A 
pBAD24-acrZ G30A This study N/A 
pBAD24-acrZ E31A This study N/A 
pBAD24-acrZ F33A This study N/A 
pEB354-acrB from Escherichia coli MG1655 (GeneID: 
945108) cloned into XbaI and XhoI sites to create T25-
AcrB fusion Hobbs et al., 2012  N/A 
pUT18-acrZ from Escherichia coli MG1655 (GeneID: 
945365) cloned into HindIII and EcoRI sites to create 
AcrZ-T18 fusion Hobbs et al., 2012  N/A 
pUT18-acrZ P16A This study N/A 
pUT18-acrZ P16A V17P This study N/A 
pUT18-acrZ P16A V18P This study N/A 
pUT18-acrZ P16A M19P This study N/A 
pUT18-acrZ P16A A20P This study N/A 
pUT18-acrZ M19P This study N/A 
pUT18-acrZ A20P This study N/A 
pUT18-acrZ P16G This study N/A 
pUT18-acrZ V15G P16G This study N/A 
pUT18-acrZ P16G V17G This study N/A 
pUT18-acrZ S7A This study N/A 
pUT18-acrZ V15A This study N/A 
pUT18-acrZ M19A This study N/A 
pUT18-acrZ I22A This study N/A 
pUT18-acrZ L23A This study N/A 
pUT18-acrZ I26A This study N/A 
pUT18-acrZ L29A This study N/A 
pUT18-acrZ G30A This study N/A 
pUT18-acrZ E31A This study N/A 
pUT18-acrZ F33A This study N/A 
Software and Algorithms 




ISOLDE Croll, T.I., 2018 https://isolde.cimr
.cam.ac.uk/ 
PHENIX Liebschner et al., 2019 https://www.phen
ix-online.org/ 
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Motioncor2 Zheng et al., 2017 https://emcore.uc
sf.edu/ucsf-
motioncor2 
Gctf Zhang et al., 2016 https://www.mrc-
lmb.cam.ac.uk/kzh
ang/ 
Chimera Pettersen et al., 2004 https://www.cgl.u
csf.edu/chimera/ 
ResMap Kucukelbir et al., 2014 https://sourceforg
e.net/projects/res
map-latest/ 
PyMOL DeLano, 2002 https://pymol.org/
2/ 
Coot Emsley et al., 2010 http://www.ccp4.a
c.uk/index.php 
EMRinger Barad et al., 2015 https://github.com
/fraser-
lab/EMRinger 
MOLPROBITY Chen et al., 2010 http://molprobity.
biochem.duke.edu 
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Figure S1. Related to Figure 1. Cryo-EM of AcrBZ in saposin A-nanodisc. (A) 
Representative cryo-EM micrograph image of AcrBZ in saposin A-nanodisc. The image 
has been corrected for drift. (B) Typical two- dimensional class averages of the particles. 
(C) Gold-standard Fourier Shell Correlation indicating the resolution of the density maps. 
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Shown are FSC plots generated between reconstructions from random halves of the data. 
(D) Local resolution estimation by ResMap of AcrBZ. (E) Details of structure-map overlay 








Figure S2. Related to Figure 3. Structural changes associated with AcrZ binding. 
Overlay of  AcrB (grey; partially transparent) and AcrBZ (colored) protomers in L, T, O, 
conformation from cryo-EM derived structures of protein(s) reconstituted in E. coli lipids 
inside a saposin A-disc. To facilitate visualisation, only part of the protein is displayed for 
which changes were greatest: PC1/2, PN2, I2, TMH 2, TMH 8, TMH 10-12, and TMH 4-
6 (i.e. reference frame). Color Code: PC2, pink; PN2, purple; PC1, dark green; TMH 8, 
orange; TMH 4-6, navy blue; TMH 2, cyan; TMH 10-12, blue; I2, grey. Displayed are 
PC1/2, PN2, I2, TMH 2, TMH 8, TMH 10-12, and TMH 4-6 (i.e. reference frame), i.e. 























Figure S3. Related to Figure 4. Mutation of AcrZ interfacial residues. (A) The sequence 
of AcrZ. Interfacial residues predicted by previous structure and mutated are highlighted 
in red. (B) Structure of AcrB (grey) and AcrZ (blue) with interfacial residues indicated in 
red. (C) Split adenylate cyclase two-hybrid assays of the interaction between plasmid-
encoded T25-AcrB and the empty vector, wild type AcrZ-T18 or the indicated mutant. 
T25-AcrB and the AcrZ-T18 indicated were co-expressed in an adenylate cyclase 
deficient strain and grown to OD600 ~ 1 when cells were harvested for β-galactosidase 
activity assay. Shown are the average and standard deviation of three experiments. The 
first and second wt and vector samples are the same. (D) Exponentially-growing cultures 
of the E. coli ∆acrZ strains carrying the pBAD24 empty vector, wild type AcrZ or the 
indicated AcrZ mutant were applied across chloramphenicol gradient plates to visualize 
differences in antibiotic sensitivity. The plates were incubated overnight at 37°C and 






      
 
Figure S4. Related to Figure 5. Cardiolipin and POPG enrichment around AcrB and 
AcrBZ. (A) The number of cardiolipin (left) and POPG (right) found within 6 Å of AcrB 
(black) and AcrBZ (red or blue) throughout 5 µs of coarse-grained simulations. Data 
shown from three independent repeats. (B) Partial mass density of cardiolipin (red) and 
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POPG (blue) and around AcrB (white space in the middle of the graph). This is normalized 
to the number of cardiolipin and POPG in the membrane. (C) Same analysis performed 
on AcrBZ. (D)  The number of each lipid species divided by the total number of lipids in 







Figure S5. Related to Figure 6. Structural comparison of substrate entry site between 
saposin A-nanodisc reconstituted AcrB and AcrBZ with cardiolipin enrichment. L 
protomers of cryo-EM derived AcrB (in grey; partially transparent) reconstituted in E. coli 
lipids inside a saposin A-nanodisc and AcrBZ (blue) reconstituted in E. coli lipids enriched 
with cardiolipin inside a saposin A-nanodisc. Channel 2 entry is restricted by a loop region 
of PC1/2 (red) for substrate entry from the outer leaflet of the inner membrane. In the 
surface view, the entry site is open in case of the AcrBZ complex with 5% cardiolipin 
addition (A) and closed in AcrB without cardiolipin enrichment (B). The channel 1 entry 
site, protruding from the periplasm, is slightly lowered in case of AcrBZ (C), for easier 
access from above the membrane outer surface area, and elevated in case of AcrB (D). 
The dashed lines indicate the approximate level of the outer leaflet boundary with the 








Figure S6. Related to Figure 6. Translocation of chloramphenicol into the binding site of 
AcrBZ and AcrB unaffected by the switch loop conformation. (A) A steered molecular 
dynamic simulation was performed whereby a chloramphenicol molecule was pulled from 
the periplasmic space into the deep binding pocket of the L protomer of AcrBZ. Views 
from the top (left) and side (right) of the protein are shown. Snapshots of chloramphenicol 
(nitrite group is orange, hydroxyl is green, and the rest is grey as shown in inset) and the 
switch loop (red) were taken every 1 ns of the simulation. The approximate position of the 
deep binding pocket is indicated by the black dotted circle. (B) A steered molecular 
dynamic simulation performed for AcrB showing a similar entry pathway of the drug into 
the protein. These simulations indicate that the switch loop is flexible and is able to allow 





Figure S7. Related to Figure 6. Chloramphenicol binds more stably to AcrBZ with 5% 
cardiolipin. (A) and (B) Snapshots of chloramphenicol (same colour scheme as Figure 
4—Figure supplement 4) bound to the binding site of the T protomer of AcrBZ and AcrB, 
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4b are shown in red. (C) and (D) The coordinate along the z-axis (perpendicular to the 
plane of the membrane) of the nitrite and hydroxyl moieties during two independent 
simulations (Sim1 and Sim2) with AcrBZ and AcrB, respectively. Arrows in (D) indicate 
the time points at which the drug molecule flipped its orientation within the binding site. 
(E) and (F) The most frequently sampled conformation of the drug molecule from these 
simulations. The binding of chloramphenicol to AcrBZ was potentially stabilised by a pi-
stacking interaction between its nitrobenzene ring and either F178 and F615. This 
interaction was absent in the AcrB simulations and the closest aromatic residue was 


































saposin A disc 
Chloramphenicol                 
AcrB  
saposin A disc 
Minocycline 
AcrBZ  




saposin A disc + 
5% cardiolipin 
Minocycline 
PDB code 6SGS 6SGU 6SGR 6SGT 
EMDB code  
 
10183 10185 10182 10184 
Data collection     
Microscope FEI Titan Krios FEI Titan Krios FEI Titan Krios FEI Titan Krios 
Voltage (kV) 300 300 300 300 
Detector Falcon III K2 Falcon III Falcon III 
Mode Counting Counting Counting Counting 
Nominal magnification 









Electron dose, per frame (e–/Å2) 0.350 1.335 0.586 0.919 
Electron dose, total (e–/Å2) 26.25 53.4 46.9 44.1  
Defocus range (µm), step (µm) 
Exposure (s) 
Frames 
Number of micrographs 
 
















Reconstruction     
Software RELION-3.0 RELION-3.0 RELION-3.0 RELION-3.0 
Number of particles used 94,507 414,786 95,775 77,593 
Final resolution, FSC0.143 (Å) 3.20 3.27 3.17 3.46 
Map-sharpening B factor (Å2) 
 
–107.0 –101.2 –99.6 –109.1 
Model composition     
Non-hydrogen atoms 54,156 52,169 54,150 52,180 
Protein residues 3,528 3,407 3,528 3,408 
 
Refinement 
    
Software Phenix-1.15.2 Phenix-1.15.2 Phenix-1.15.2 Phenix-1.15.2 
Correlation coefficient, masked 0.82 0.82 0.83 0.79 
Correlation coefficient, box 0.65 0.71 0.69 0.65 
 
Validation (proteins) 
    
MolProbity score 1.12 1.39 1.19 1.49 
Clash score, all atoms 2.03 3.26 2.14 3.28 
EMRinger score 
 
Ramachandran plot statistics 
3.39 1.65 3.52 2.47 
Favoured, overall (%) 97.21 96.03 96.78 95.38 
Allowed, overall (%) 2.79 3.94 3.22 4.53 
Outlier, overall (%) 0.00 0.03 0.00 0.09 
 
R.m.s. deviations 
    
Bond length (Å) 0.003 0.004 0.003 0.003 
Bond angle (°) 0.581 0.634 0.533 0.633 
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Table S2. Root mean square fits in angstrom for pairwise comparisons of the cryoEM structures determined 






AcrB AcrBZ AcrB + 
additional 
cardiolipin 






X 0.803 0.769 0.838 0.847 
AcrB  X 0.460 0.260 0.445 
AcrBZ   X 0.460 0.317 
AcrB + add. CL    X 0.435 
AcrBZ + add. CL     X 
 













X 0.757 0.628 0.753 0.753 
AcrB  X 0.431 0.248 0.416 
AcrBZ   X 0.435 0.322 
AcrB + add. CL    X 0.428 
AcrBZ + add. CL     X 
 













X 0.685 0.702 0.738 0.794 
AcrB  X 0.408 0.253 0.441 
AcrBZ   X 0.429 0.291 
AcrB + add. CL    X 0.435 
AcrBZ + add. CL     X 
 













X 0.601 0.588 0.636 0.559 
AcrB  X 0.368 0.228 0.358 
AcrBZ   X 0.402 0.266 
AcrB + add. CL    X 0.371 

















X 0.406 0.393 0.417 0.402 
AcrB  X 0.251 0.202 0.229 
AcrBZ   X 0.266 0.232 
AcrB + add. CL    X 0.299 
AcrBZ + add. CL     X 
 













X 0.593 0.528 0.661 0.582 
AcrB  X 0.417 0.342 0.461 
AcrBZ   X 0.520 0.234 
AcrB + add. CL    X 0.551 
AcrBZ + add. CL     X 
 













X 0.431 0.391 0.476 0.419 
AcrB  X 0.250 0.229 0.287 
AcrBZ   X 0.317 0.245 
AcrB + add. CL    X 0.281 



































X 0.412 0.335 0.460 0.346 
AcrB  X 0.331 0.267 0.321 
AcrBZ   X 0.375 0.212 
AcrB + add. CL    X 0.388 



















X 0.397 0.360 0.462 0.377 
AcrB  X 0.308 0.229 0.312 
AcrBZ   X 0.354 0.208 
AcrB + add. CL    X 0.361 
AcrBZ + add. CL     X 
 













X 0.408 0.383 0.485 0.367 
AcrB  X 0.277 0.217 0.302 
AcrBZ   X 0.384 0.216 
AcrB + add. CL    X 0.351 































X 0.652 0.519 0.678 0.553 
AcrB  X 0.536 0.365 0.694 
AcrBZ   X 0.671 0.452 
AcrB + add. CL    X 0.869 
AcrBZ + add. CL     X 
 













X 0.618 0.698 0.658 0.687 
AcrB  X 0.476 0.266 0.418 
AcrBZ   X 0.503 0.405 
AcrB + add. CL    X 0.475 

















X 0.557 0.495 0.644 0.530 
AcrB  X 0.382 0.294 0.365 
AcrBZ   X 0.484 0.286 
AcrB + add. CL    X 0.484 
































X 0.912 0.861 0.883 0.835 
AcrB  X 0.421 0.288 0.511 
AcrBZ   X 0.458 0.370 
AcrB + add. CL    X 0.511 
AcrBZ + add. CL     X 
 













X 0.942 0.847 0.966 0.928 
AcrB  X 0.390 0.250 0.373 
AcrBZ   X 0.411 0.274 
AcrB + add. CL    X 0.416 
AcrBZ + add. CL     X 
 













X 1.344 1.229 1.328 1.207 
AcrB  X 0.408 0.256 0.406 
AcrBZ   X 0.434 0.312 
AcrB + add. CL    X 0.432 
AcrBZ + add. CL     X 
 
 




































X 0.926 0.794 0.922 0.803 
AcrB  X 0.547 0.317 0.524 
AcrBZ   X 0.552 0.372 
AcrB + add. CL    X 0.552 
AcrBZ + add. CL     X 
 













X 1.008 0.870 0.992 0.850 
AcrB  X 0.421 0.258 0.441 
AcrBZ   X 0.459 0.275 
AcrB + add. CL    X 0.487 
AcrBZ + add. CL     X 
 













X 0.916 0.880 0.949 0.819 
AcrB  X 0.486 0.273 0.446 
AcrBZ   X 0.559 0.332 
AcrB + add. CL    X 0.520 

















Table S3. Oligonucleotides. Related to Figure 4. 








































lr12 (rev Q5 mutagenesis primer acrZ P16A A20P) GCTACCATGATTACGGCG 




lr20 (rev Q5 mutagenesis primer acrZ P16A V17P) ATTACGGCGAATACCAGAC 




lr22 (rev Q5 mutagenesis primer acrZ P16A V18P) ATGATTACGGCGAATACC 
































lr51 (rev Q5 mutagenesis primer acrZ A20P) GGTACCATGATTACGGCG 




mo21 (rev Q5 mutagenesis primer acrZ S7A)  TCTAACATCAAGCTTGGC 
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mo33 (rev Q5 mutagenesis primer acrZ I22A) CAGGTACCATGATTACGG 




mo35 (rev Q5 mutagenesis primer acrZ L23A) ATCACGACAGGTACCATG 




mo46 (rev Q5 mutagenesis primer acrZ L29A) TAAATCAGACCCAGGATG 












mo50 (rev Q5 mutagenesis primer acrZ E31A)  TAAATCAGACCCAGGATG 




mo52 (rev Q5 mutagenesis primer acrZ F33A)  
GACCGTAAATCAGACCCA
G 




mo68 (rev Q5 mutagenesis primer acrZ P16A) ACGGCGAATACCAGACTT 
 
 
